Clinical trials: Streptococcus Pyogenes Infection
Pharyngitis
APC-231 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) in Pediatric Patients With Strep Throat
The purpose of this study is to evaluate the efficacy and safety of APC-231 QD for 7 days in the bacteriological outcome at the Test of Cure Visit.
- Trial name
- NCT00100126
- Testing
- Amoxicillin Pulsatile Release Multiparticluate Sprinkle
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- Advancis Pharmaceutical Corporation
Streptococcus Pyogenes Infection, Pharyngitis
Clinical Performance of the Checkable Medical At-Home Strep A Test
The Checkable Medical At-Home Strep A Test is a rapid chromatographic immunoassay for the qualitative detection of Group A Strep (GAS) antigens from throat swabs.
- Conditions
- Streptococcus Pyogenes Infection, Pharyngitis, Respiratory Tract Infections
- Trial name
- NCT05107362
- Testing
- untrained lay user performs investigational diagnostic test
- Where
- 22 sites in United States
- Volunteers
- 1,347 people
- Sponsor
- Checkable Medical Inc
Tonsillitis, Pharyngitis
TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults
This is a multinational, randomized (1:1), double blind, comparator-controlled, 2 parallel treatment group study in subjects equal to or over 13 years of age, with Streptococcus pyogenes tonsillitis/pharyngitis (T/P).
- Trial name
- NCT00315549
- Testing
- Telithromycin, Penicillin
- Where
- 4 sites in United States, Argentina and 2 more
- Volunteers
- 233 people
- Sponsor
- Sanofi
Pharyngitis
Pharyngitis,Group A Streptococcal Infection,Rapid Streptococcal Test,Throat Swab Culture
Comparison of Immunochromatographic Test for rapid detection of group A streptococcal antigen with culture in Pediatric patients.
- Trial name
- NCT02494219
- Testing
- Rapid Immunochromatographic streptococcal test
- Where
- Qatar
- Volunteers
- 906 people
- Sponsor
- Hamad Medical Corporation
Streptococcal Pharyngitis, Group A Streptococcal Infection
A Multicenter Evaluation of SalivIQ™ Strep A for Detecting Group A Streptococcus From Saliva and Throat Swabs in Patients With Acute Pharyngitis
The goal of this observational study is to learn how well the SalivIQ™ Strep A test detects Group A Streptococcus, the bacteria that cause strep throat.
- Trial name
- NCT07891728
- Testing
- qPCR
- Where
- 3 sites in United States
- Volunteers
- 668 people
- Sponsor
- SalivIQ Diagnostics, Inc.
Tonsillitis, Pharyngitis
TELI TON - Telithromycin in Tonsillitis
This is a multinational, randomized (1:1), double blind, double dummy, comparator-controlled, 2 parallel treatment group study in subjects from 6 months to < 13 years of age, with Streptococcus pyogenes tonsillitis/pharyngitis…
- Trial name
- NCT00315042
- Testing
- Telithromycin (HMR3647), Penicillin
- Where
- 5 sites in United States, Argentina and 3 more
- Volunteers
- 314 people
- Sponsor
- Sanofi
Group A Streptococcal Infection
Performance of Ellume·Lab Group A Strep Test Versus Culture for the Rapid Detection of Group A Streptococcus in Participants With Acute Pharyngitis
Participants who meet the eligibility criteria and who consent to participation or whose parents/legal guardian consent to their participation, will be enrolled in the study for a period of up to 14 days.
- Trial name
- NCT03693495
- Testing
- ellume·lab Group A Streptococcus Test, Bacterial Culture, Polymerase Chain Reaction (PCR)
- Where
- 4 sites in New Zealand
- Sponsor
- Ellume Pty Ltd
Group A Streptococcal Infection
Performance of Ellume·Lab Group A Strep Test Versus Culture for the Rapid Detection of Group A Streptococcus in Patients With Acute Pharyngitis.
Participants who meet the eligibility criteria and who consent to participation or whose parents/legal guardian consent to their participation, will be enrolled in the study for a period of up to 14 days.
- Trial name
- NCT03171350
- Testing
- ellume.lab Group A Streptococcus Test
- Where
- 8 sites in Australia
- Volunteers
- 132 people
- Sponsor
- Ellume Pty Ltd
Group A Streptococcal Infection
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and immunogenicity of VAX-A1 in healthy adults 18-40 years of age.
- Trial name
- NCT07616934
- Testing
- VAX-A1 Low, VAX-A1 Mid, VAX-A1 High
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Bacterial Infection Due to Streptococcus, Group B, Streptococcus Agalactiae
Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.
The objective of this extension study is the initial assessment of safety and immunogenicity of the second dose of GBS Trivalent Vaccine following the time interval that is close to the inter-pregnancy interval observed in the…
- Trial name
- NCT02690181
- Testing
- GBS Trivalent Vaccine
- Where
- Belgium
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Streptococcal Infections
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults
The purpose of this study is to assess the safety of 3 doses of 2 new Strep A vaccine formulations, one with an Alum adjuvant, and the other with AS37 adjuvant.
- Trial name
- NCT07085702
- Testing
- Low dose Strep A Alum, Medium dose Strep A Alum, High dose Strep A Alum
- Where
- 2 sites in Australia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pharyngitis, Infective
Validation of the GenePOC Strep A, C/G Assay for Detecting Group A, C and G β-hemolytic Streptococcus From Throat Swabs.
The primary purpose of this clinical investigation is to establish the performance of the GenePOC Strep A, C/G assay on the revogene.
- Trial name
- NCT03422341
- Testing
- Comparison between GenePOC CR and Reference Method
- Where
- 8 sites in United States, Canada
- Volunteers
- 497 people
- Sponsor
- Meridian Bioscience, Inc.
Pharyngitis, Tonsillitis
APC-111 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) for 10 Days in Patients With Strep Throat
The purpose of the this study is to evaluate the safety of efficacy of APC-111 775 mg MP tablet once daily dosing for 7 days for treating patients with strep throat.
- Trial name
- NCT00095368
- Testing
- Amoxicillin Pulsatile Release Multiparticulate Tablet (drug)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Advancis Pharmaceutical Corporation